文献速递胸部肿瘤放疗

小细胞肺癌放化疗后复发部位与预后因素

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-11-06

回顾性单中心研究纳入43例接受同步放化疗的局限期小细胞肺癌患者,放疗总剂量45 Gy、每次1.5 Gy每日两次。13例(30%)出现局部或区域复发,所有复发病灶均接受了92%–106%的处方剂量,未观察到孤立性淋巴结失败,支持选择性淋巴结照射。

要点

  • 同步放化疗后30%患者出现局部或区域复发,多数位于原发肿瘤或初始受累淋巴结。
  • 所有局部区域复发病灶均接受了92%–106%的处方剂量。
  • 未观察到孤立性淋巴结失败,支持选择性淋巴结照射策略。

核心结论

  • 大多数复发发生在原发肿瘤或初始受累淋巴结内或远处,未登记孤立性淋巴结失败病例。

研究设计与样本

  • 回顾性单中心研究纳入43例连续接受同步放化疗的局限期小细胞肺癌患者,分期包括FDG-PET/CT。
  • 所有患者接受三维适形放疗,总剂量45 Gy,每次1.5 Gy每日两次,与第一或第二周期化疗同步开始。

主要发现

  • 13例(30%)患者出现局部或区域复发:6例在原发肿瘤体积内,5例在初始受累淋巴结内,1例同时在原发肿瘤和初始受累淋巴结内(异时性),1例在初始淋巴结病变内外。
  • 所有局部区域复发病灶均接受了92%–106%的处方剂量。

关键数值与推荐

  • 放疗总剂量45 Gy,每次1.5 Gy每日两次。
  • 局部区域复发病灶接受处方剂量的92%–106%。
  • 未登记孤立性淋巴结失败病例,支持选择性淋巴结照射,可能对上纵隔淋巴结病变患者加照锁骨上区。

临床怎么用

  • 对于接受同步放化疗的局限期小细胞肺癌患者,选择性淋巴结照射是可行的,未观察到孤立性淋巴结失败。
  • 上纵隔淋巴结病变患者可考虑加照锁骨上区。

局限性

  • 回顾性单中心研究,样本量43例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Concurrent radiochemotherapy (RCHT) is standard treatment in locally advanced small cell lung cancer (SCLC) patients. Due to conflicting results on elective nodal irradiation (ENI) or selective node irradiation (SNI) there is no clear evidence on optimal target volumes. Therefore, the purposes of this study were to assess the sites of recurrent disease in SCLC and to evaluate the feasibility of SNI versus ENI. METHODS: A retrospective single-institution study of 43 consecutive patients treated with RCHT was performed. After state-of-the-art staging including FDG-PET/CT, all patients underwent three-dimensional conformal radiotherapy to a total dose of 45 Gy in twice-daily fractions of 1.5 Gy starting concurrently with the first or second chemotherapy cycle. All sites of loco-regional recurrences were correlated to the initial tumor and dose delivered. The impact of potential prognostic variables on outcome was evaluated using the Cox-regression model. RESULTS: 13 patients (30%) relapsed locally or regionally: six within the initial primary tumor volume, five within the initially affected lymph nodes, one metachronously within primary tumor and initially affected lymph nodes, and one both inside and outside of the initial nodal disease. All sites of loco-regional recurrence had received 92-106% of the prescribed dose. CONCLUSION: In our study most recurrences occurred within the primary tumor or initially affected lymph nodes, or distantly. We did not register any case of isolated nodal failure, supporting the use of selective nodal irradiation, possibly with the addition of supraclavicular irradiation in patients with nodal disease in the upper mediastinum.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bütof R, Gumina C, Valentini C, et al. Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. Clin Transl Radiat Oncol. 2017. PMID: 29594227. doi:10.1016/j.ctro.2017.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。